Cassava Sciences downgraded by H.C. Wainwright
$SAVA
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/26/2024 | Buy → Neutral | H.C. Wainwright | |
| 10/8/2024 | $116.00 | Neutral → Buy | H.C. Wainwright |
| 7/1/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/16/2022 | $44.00 | Buy → Neutral | B. Riley Securities |
| 1/24/2022 | $108.00 → $72.00 | Buy | B. Riley Securities |
| 7/20/2021 | $97.00 → $124.00 | Buy | HC Wainwright & Co. |
| 7/15/2021 | $100.00 | Overweight → Neutral | Cantor Fitzgerald |
| 7/7/2021 | $80.00 → $190.00 | Buy | Maxim Group |
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
8-K/A - CASSAVA SCIENCES INC (0001069530) (Filer)
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam's favorable safety profile in these studies Exploratory post-hoc analyses offer informative insights AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced publication of the article Phase 3 randomized clinica
Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral
H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00
H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral
Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for c
AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time. Event Details: Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast: https://lifescievents.com/event/cassava/ A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnolog
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time. Event details: Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)